Ask AI
Schizophrenia Treatment Switch

CE / CME

Switching Treatment in Schizophrenia: Managing Long-term Adverse Effects

Nurse Practitioners/Nurses: 0.50 Nursing contact hour, including 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Psychologists: 0.50 APA CE Credit

Released: July 31, 2026

Expiration: July 30, 2027

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A patient with schizophrenia has had a partial response to antipsychotic treatment but is concerned about long-term adverse effects (AEs). The healthcare professional (HCP) is reviewing different treatment mechanisms, including dopamine receptor–modulating agents and a muscarinic cholinergic.

Based on the patient’s partial response and concern about long-term AEs, which statement should guide your selection between dopaminergic and muscarinic treatment approaches?

2.

An HCP is reviewing emerging evidence for xanomeline/trospium in adults with schizophrenia and wants to place the data in appropriate clinical context.

Which interpretation of the current clinical evidence for xanomeline/trospium is most appropriate?

3.

A patient with schizophrenia is being transitioned to xanomeline/trospium after experiencing poor tolerability with a dopamine-blocking antipsychotic. The patient and family ask how to take the medication and what AEs they should monitor.

Which counseling strategy would you use when initiating xanomeline/trospium?